SOPHiA GENETICS (NASDAQ:SOPH) Coverage Initiated at Craig Hallum

Equities research analysts at Craig Hallum assumed coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a research report issued to clients and investors on Wednesday, MarketBeat reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. Craig Hallum’s target price indicates a potential upside of 254.84% from the stock’s current price.

SOPHiA GENETICS Trading Down 8.8 %

Shares of SOPHiA GENETICS stock opened at $3.10 on Wednesday. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. SOPHiA GENETICS has a 12-month low of $2.70 and a 12-month high of $7.37. The company has a market capitalization of $202.66 million, a price-to-earnings ratio of -2.84 and a beta of 0.99. The firm’s 50-day moving average price is $3.43 and its two-hundred day moving average price is $3.92.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The firm had revenue of $15.85 million for the quarter, compared to analyst estimates of $15.90 million. During the same quarter in the prior year, the business posted ($0.21) EPS. On average, analysts forecast that SOPHiA GENETICS will post -0.98 earnings per share for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of the business. Banque Cantonale Vaudoise grew its position in SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after acquiring an additional 9,000 shares during the last quarter. Green Alpha Advisors LLC acquired a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at approximately $79,000. Federated Hermes Inc. grew its holdings in shares of SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after purchasing an additional 23,000 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after purchasing an additional 86,764 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.